Highlights of QBL subsidiary on MMJ DEVELOPMENT.
Post# of 103003
(Total Views: 244)
Posted On: 05/22/2018 2:24:33 PM
Highlights of QBL subsidiary on MMJ DEVELOPMENT.
• The board has an effective mix of both pharmaceutical and cannabis expertise working on MCL’s drug development strategy
• MCL’s strategy will position Canntab as a reliable and medical based ‘product of choice’
• Revenue is targeted in Australia in 2018 via Canntab sales under the Special Access Scheme
• MCL is targeting broader adoption in pain relief through the clinical trial process
Here you have the opportunity to take advantage on facts and info from QBL. Like the ”QBL on ASX” chapter, who can provide verified facts; here is also regulated on-line stockbrokers suggestion, no games info and a good sum up. Voluntary suspension is requested regarding a significant and strategic acquisition by QBL’s subsidiary Medical Cannabis Limited until Friday 25 th or before. Contact information to the QBL Investor service, who can reply on questions.
https://www.queenslandbauxite.com/
• The board has an effective mix of both pharmaceutical and cannabis expertise working on MCL’s drug development strategy
• MCL’s strategy will position Canntab as a reliable and medical based ‘product of choice’
• Revenue is targeted in Australia in 2018 via Canntab sales under the Special Access Scheme
• MCL is targeting broader adoption in pain relief through the clinical trial process
Here you have the opportunity to take advantage on facts and info from QBL. Like the ”QBL on ASX” chapter, who can provide verified facts; here is also regulated on-line stockbrokers suggestion, no games info and a good sum up. Voluntary suspension is requested regarding a significant and strategic acquisition by QBL’s subsidiary Medical Cannabis Limited until Friday 25 th or before. Contact information to the QBL Investor service, who can reply on questions.
https://www.queenslandbauxite.com/
(0)
(0)
Robert
Scroll down for more posts ▼